Neurodevelopmental disorder therapy

1. A method of ameliorating biochemical and functional abnormalities associated with methyl-CpG binding protein 2 defects (MeCP2 defects) in a subject by administering to the subject in need thereof a composition comprising a therapeutically effective amount of a therapeutic agent selected from the group of Anavex2-73, an analog of Anavex2-73, and a combination thereof.

2. The method of claim 1 , wherein the biochemical and functional abnormalities associated with MeCP2 defects manifest as neurodevelopmental or neurological diseases.

3. The method of claim 2 , wherein the neurodevelopmental or neurological diseases comprises multiple sclerosis, Rett Syndrome, cerebral palsy, Angelman syndrome, Williams syndrome, pervasive developmental disorder not otherwise specified (PDD-NOS), childhood disintegrative disorder, Smith-Magenis syndrome, non-syndromic mental retardation, idiopathic neonatal encephalopathy, idiopathic cerebral palsy, or autism spectrum disorder.

4. The method of claim 1 , wherein the biochemical and functional abnormalities associated with MeCP2 defects comprises abnormal breathing, abnormal cardiac function, abnormal feeding or choking, weight gain failure, abnormal sleep or seizure.

5. The method of claim 1 , wherein the therapeutic agent is Anavex2-73.

6. The method of claim 1 , wherein the therapeutic agent is the analog of Anavex2-73 selected from the group consisting of A1-41, A19-144, and a combination thereof.

7. The method of claim 1 , wherein the therapeutically effective amount is a dosage from about 0.5 mg/day to about 100 mg/day.

8. The method of claim 1 , wherein the composition is selected from a group consisting of an oral composition, a transdermal composition and a parenteral composition.

9. The method of claim 1 , wherein the subject is an adult, a child, or an infant.

10. The method of claim 1 , wherein the subject is a child or an infant and the dosage ranges from about 0.5 mg/day to about 20 mg/day.

11. A method of treating disorders associated with methyl-CpG binding protein 2 defects (MeCP2 defects) in a subject by administering to the subject in need thereof a composition comprising a therapeutically effective amount of a therapeutic agent selected from the group of Anavex2-73, an analog of Anavex2-73, and a combination thereof.

12. The method of claim 11 , wherein the disorders associated with MeCP2 defects comprises a neurodevelopmental or a neurological disease.

13. The method of claim 12 , wherein the neurodevelopmental or neurological disease comprises multiple sclerosis, Rett Syndrome, cerebral palsy, Angelman syndrome, Williams syndrome, pervasive developmental disorder not otherwise specified (PDD-NOS), childhood disintegrative disorder, Smith-Magenis syndrome, non-syndromic mental retardation, idiopathic neonatal encephalopathy, idiopathic cerebral palsy, or autism spectrum disorder.

14. The method of claim 13 , wherein the neurodevelopmental or neurological diseases is treated by normalizing breathing, normalizing cardiac function, normalizing feeding and avoiding choking, obtaining weight gain, normalizing sleep or reducing seizure.

15. The method of claim 11 , wherein the therapeutic agent is Anavex2-73.

16. The method of claim 11 , wherein the therapeutic agent is the analog of Anavex2-73 selected from the group consisting of A1-41, A19-144, and a combination thereof.

17. The method of claim 11 , wherein the therapeutically effective amount is a dosage from about 0.5 mg/day to about 100 mg/day.

18. The method of claim 11 , wherein the composition is selected from a group consisting of an oral composition, a transdermal composition and a parenteral composition.

19. The method of claim 11 , wherein the subject is an adult, a child, or an infant.

20. The method of claim 11 , wherein the subject is a child or an infant and the dosage ranges from about 0.5 mg/day to about 20 mg/day.